C.M. Laumont et al., “Noncoding regions are the main source of targetable tumor-specific antigens,” Sci Transl Med, 10:eaau5516, 2019. In pursuit of safe and effective cancer therapies, researchers ...

rely on the immune system recognizing cancer-specific ‘non-self’ antigens. These antigens are bound to human leukocyte ...

Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now ...

including chimeric antigen receptor-T cell and T cell receptor-based therapies, rely on the engineering of single, highly tumor-specific receptors that when expressed in T cells target the body ...

The ADCs mAb attaches to specific antigens on the surface of tumor cells, and ADCs are internalized into tumor cells during the formation of the antibody–antigen complex. ADCs are typically ...

These approaches include monoclonal antibodies against tumor antigens, checkpoint inhibitors that block tumors from accessing suppressive proteins on immune cells, and chimeric antigen receptor (CAR) ...

Initially designed for hematological malignancies, CAR-T therapy is now being expanded to target solid tumors using specialized CAR-T cells that attack specific antigens. Ongoing clinical trials are ...

Advancements in Antigen Selection for CRC CAR-T Cell Therapies Introducing specific targets for CAR-T cell therapy in CRC is essential ... 37 Natural killer group 2 member D ligands are stress-induced ...

Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now ...